TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23073143
Drug: 100-mg sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg sarpogrelate IR 3 times at a 6-h interval
Study: 23073143
Drug: 300-mg sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg sarpogrelate CR once
Study: 20624624
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg for 7 days before surgery
Study: 20624624
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg for 7 days before surgery
Study: 17147088
Drug: Senna 12
Normalized name: senna 12 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna 12 mg and Magnesium Sulphate 15 mg the day before colonoscopy
Study: 17147088
Drug: Polyethylene Glycol-based
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene Glycol-based solution of two litres plus 4 tablets of Bisacodyl the day before the exam
Study: 10720544
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 times a week) for 12 weeks
Study: 1337322
Drug: Molsidomine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (16 mg)
Study: 24773615
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris extract (7.5 mg/day)
Study: 23021433
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral glutamine (0.5 g kg(‐1) d(‐1)) for 4 months
Study: 23021433
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral glutamine (0.5 g kg(‐1) d(‐1)) for 5 hours
Study: 16054408
Drug: Socio-economic factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socio-economic factors (e.g. financial strain)
Study: 12848286
Drug: High-DHA eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-DHA eggs (135 mg DHA/egg)
Study: 12848286
Drug: Ordinary eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary eggs (18 mg DHA/egg)
Study: 9004188
Drug: Multi-segment absorption
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-segment absorption model for diclofenac sodium
Study: 9004188
Drug: Conventional pharmacokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacokinetic method (first-order absorption)
Study: 9004188
Drug: Multi-segment absorption
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-segment absorption models
Study: 1480873
Drug: Manual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual treatment of pelvic joint dysfunction
Study: 1480873
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (massage)
Study: 3758947
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (0.6 microgram) + Hepatitis B immune globulin (500 IU)
Study: 3758947
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine only (0.6 microgram)
Study: 24849077
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (self-measurement of pressure pain sensitivity followed by acupressure)
Study: 22273342
Drug: Nurse-led cognitive
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led cognitive behavioral group therapy once a week for 12 weeks
Study: 22273342
Drug: Nurse-led cognitive
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led cognitive behavioral group therapy
Study: 8694673
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg
Study: 8694673
Drug: Valaciclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1000 mg
Study: 12534609
Drug: Valaciclovir 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 2000 mg
Study: 7828385
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg lifibrol for 4 weeks
Study: 7828385
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lifibrol for 4 weeks
Study: 7828385
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg lifibrol for 4 weeks
Study: 7828385
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lifibrol for 4 weeks
Study: 7828385
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg lifibrol for 4 weeks
Study: 7828385
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg lifibrol for 12 weeks
Study: 7828385
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lifibrol for 12 weeks
Study: 7828385
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lifibrol for 12 weeks
Study: 2193858
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid administration (50 mg Ultracortene‐H) with 2 mg morphine hydrochloride
Study: 2193858
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine hydrochloride without Ultracortene‐H
Study: 23662047
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus Azelnidipine (16 mg/day)
Study: 23662047
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus Amlodipine (5 mg/day)
Study: 21566261
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DHEA once daily
Study: 10980214
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg/day
Study: 10980214
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg/day and Pravastatin 40 mg/day
Study: 3490077
Drug: Periurethral injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periurethral injections of 10 ml 0.25% Bupivacaine, administered three times in 2-week intervals.
Study: 28339166
Drug: Avatrombopag; single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag; single doses under fasted and fed conditions.
Study: 28339166
Drug: Avatrombopag; single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag; single dose.
Study: 28339166
Drug: Avatrombopag; general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag; general administration.
Study: 22474954
Drug: Topical ointment
Normalized name: Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ointment prepared from Morinda citrifolia stem extract
Study: 20837589
Drug: Stimulant monotherapy
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant monotherapy optimization with methylphenidate preparation (once-daily, triphasic release) and behavioral therapy
Study: 18394875
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination (SFC) 50microg/250microg + 1 placebo tablet
Study: 17050557
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination (SFC)
Study: 7706786
Drug: Synthetic verotoxin
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic verotoxin (VT, shiga‐like toxin) Pk‐trisaccharide receptor sequences attached to Chromosorb (Synsorb‐Pk)
Study: 1980979
Drug: Synthetic detergent
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic detergent preparation of pH 5.5
Study: 1980979
Drug: Synthetic detergent
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic detergent preparation of pH 7.0
Study: 7234652
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or minor analgesic therapy
Study: 7234652
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Indomethacin
Study: 30621789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prompt infertility treatment)
Study: 27254026
Drug: Chemotherapy (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Cisplatin and 5-fluorouracil)
Study: 27254026
Drug: Chemoradiotherapy (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (Cisplatin and 5-fluorouracil with concurrent radiotherapy 40 Gy)
Study: 17627724
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment protocol (ITP) with sildenafil and cognitive-behavior sex therapy (CBST) for the first 4 weeks, followed by continued ITP for the last 4 weeks
Study: 17627724
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment protocol (ITP) with sildenafil and cognitive-behavior sex therapy (CBST) for the entire 8 weeks
Study: 15675894
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1 g three times a day for 2 weeks)
Study: 11849797
Drug: Amifostine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (300 mg/m(2) administered 15-30 min before RT for 6-7.5 weeks)
Study: 11849797
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy and carboplatin (90 mg/m(2) infusion once per week before RT)
Study: 25879690
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (100 g/day) + placebo capsule
Study: 25879690
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule + conventional yogurt (100 g/day)
Study: 25879690
Drug: Conventional yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yogurt (100 g/day) + placebo capsule
Study: 23813627
Drug: CRP >1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP >1 mg/L
Study: 23735179
Drug: Vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol (VI) 50 μg
Study: 22241764
Drug: Vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol (VI) 3, 6.25, 12.5, 25, or 50 μg
Study: 9493699
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of isradipine 2.5 mg plus spirapril 3 mg
Study: 7687157
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 23% saturated hypertonic saline
Study: 7687157
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 7.5% hypertonic saline
Study: 7687157
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 7.5% saline with 6% dextran 70
Study: 3599565
Drug: Amobarbital 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amobarbital 80 mg
Study: 2660556
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g twice daily
Study: 27781419
Drug: Tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form of mycophenolate mofetil
Study: 27781419
Drug: Capsule form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule form of mycophenolate mofetil
Study: 26200980
Drug: AVI-7288 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-7288 (1 mg, 4 mg, 8 mg, 12 mg, or 16 mg per kilogram of body weight)
Study: 21661445
Drug: Domperidone (10mg)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10mg) with 50 mL of water
Study: 21661445
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of water alone
Study: 15165089
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus cisplatin (20mg/m2 cisplatin 1 h before radiotherapy, given on days 1-5 of the second and sixth treatment weeks)
Study: 3653081
Drug: Fentanyl (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (any dose)
Study: 9217590
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg i.v. cocaine
Study: 9217590
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg i.v. cocaine
Study: 8353352
Drug: Celiac plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac plexus block (30 mL of 0.25% bupivacaine)
Study: 8353352
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 mL of normal saline)
Study: 3301504
Drug: Propafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450 mg or 900 mg daily
Study: 27160639
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg and titrated to 300 mg)
Study: 25612082
Drug: Skimmed milk,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skimmed milk, whey, casein (all milk-based drinks 35g protein/L)
Study: 23786940
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg/Lercanidipine 10 mg
Study: 20442614
Drug: Massage intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage intervention (10 to 15 minutes daily starting at 15 days old)
Study: 12797850
Drug: Modern medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern medical therapies
Study: 12797850
Drug: Conservative surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative surgical therapies
Study: 8652316
Drug: Morphine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (bolus dose 2 mg, lockout time 10 min)
Study: 8652316
Drug: Pethidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (bolus dose 20 mg, lockout time 10 min)
Study: 8652316
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Pethidine
Study: 30802204
Drug: Ferumoxytol 1.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol 1.02 g (2 × 510 mg)
Study: 30802204
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose 1.0 g (10 × 100 mg)
Study: 12362928
Drug: Estradiol Transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol Transdermal System (Mylan Pharmaceuticals, Inc.)
Study: 10434162
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg kg‐1 and suxamethonium 1.5 mg kg‐1 (group TS)
Study: 10434162
Drug: Alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 10 micrograms kg‐1 and propofol 3 mg kg‐1 (group PA)
Study: 7598289
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (1.5 mL bupivacaine 0.75% with fentanyl 10 micrograms)
Study: 2240678
Drug: High thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High thoracic segmental epidural anesthesia with bupivacaine (4.2 ml, 0.75%)
Study: 773498
Drug: Labetalol 300
Normalized name: labetalol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 300 mg daily
Study: 773498
Drug: Labetalol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 600 mg daily
Study: 11764135
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (conventional treatment)
Study: 1672049
Drug: esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1 mg/kg and fentanyl 2 micrograms/kg
Study: 6134622
Drug: Intravenous oxmetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxmetidine (100 mg)
Study: 6134622
Drug: Oral oxmetidine
Normalized name: cimetidine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxmetidine (200 mg)
Study: 24588905
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) 5 mg, single intravenous infusion
Study: 20213586
Drug: Gynostemma pentaphyllum
Normalized name: GYNOSTEMMA PENTAPHYLLUM TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynostemma pentaphyllum tea (6 g daily for 12 weeks)
Study: 16573847
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg/d, increased by 50 mg weekly to a maximum of 150 or 300 mg/d)
Study: 16342349
Drug: Levosimendan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12 microg/kg loading dose for 15 minutes)
Study: 12105237
Drug: Phosphate binders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate binders (including sevelamer hydrochloride, magnesium-based, iron-based, and lanthanum-based compounds)
Study: 12105237
Drug: Aluminium gels
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium gels and calcium salts (historical context)
Study: 7011819
Drug: SB 7505
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB 7505 100 mg/day
Study: 27031322
Drug: 500 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 cc dextrose 5% (group A)
Study: 27031322
Drug: 500 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 cc normal saline (group B)
Study: 21925828
Drug: T5: daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: T5: daily heavy drinkers stopping early
Study: 21925828
Drug: T3: nearly
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3: nearly daily heavy drinkers
Study: 21925828
Drug: T4: daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4: daily heavy drinkers
Study: 19414713
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with sertraline hydrochloride
Study: 19414713
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment with sertraline hydrochloride
Study: 19414713
Drug: Remission with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission with treatment
Study: 17786691
Drug: 6% maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% maltodextrin, 3% lemon juice solution (carbohydrate trial)
Study: 15117902
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg bid for at least 16 weeks)
Study: 9661120
Drug: Oral liquid
Normalized name: ACAI ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid supplement containing arginine
Study: 9661120
Drug: Oral liquid
Normalized name: ACAI ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid supplement containing arginine plus omega-3 fatty acids
Study: 2246697
Drug: Phenobarbital (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (10 mg/kg)
Study: 7437245
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate (single dose)
Study: 7437245
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate (four doses)
Study: 28319552
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.5% mepivacaine (LC group)
Study: 28319552
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 1% mepivacaine (HC group)
Study: 22095836
Drug: Multivitamin, mineral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin, mineral, and herbal supplement for 8 weeks
Study: 19266367
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg PO bid continuously until disease progression
Study: 15041875
Drug: Prednisone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.8 to 1.2 mg/kg for 3 days)
Study: 11483325
Drug: HF‐ACC‐RCT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF‐ACC‐RCT with 2 cycles of 5‐FU (600 mg/m(2)/day)/carboplatinum (70 mg/m(2)) on days 1‐5 and 29‐33
Study: 11483325
Drug: Prophylactically given
Normalized name: Caries prophylactic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactically given G‐CSF (263 microg, days 15‐19)
Study: 8056991
Drug: Clemastine 2
Normalized name: clemastine 2 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 2 mg (positive control)
Study: 782307
Drug: C-1 group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-1 group: 32 patients received one dose of i.t. methotrexate at the end of induction treatment and every three months.
Study: 782307
Drug: C-2 group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-2 group: 29 patients treated by cranial irradiation (2400 r.) and five doses of i.t. methotrexate after induction of remission.
Study: 21359424
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type-A (BoNT/A) administered as a 40 μl bolus, lateral to their nose, at 24 hours, 8, 15, 22, 29 or 36 days pre-formalin test (FT)
Study: 21359424
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution 0.9% (control)
Study: 20184444
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of paracetamol
Study: 16772783
Drug: rhGH (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.05 mg/kg body weight)